April 11, 2020 1:23pm
A scorecard of earnings of 35 covered companies
(1 restating - MDXG and RENE.L still oustanding)
The current LPS (loss per share) or net income, cash positions i.e. "runways" - is a reflection of this universe's investing "status"
|
COMPANY Q4/19 |
SYMBOL | NET INCOME | Q4 & FY19 LOSS |
Q4 & FY19 LPS |
Q4/19 CASH |
RUNWAY |
|---|---|---|---|---|---|---|
| Aduro Biotech, Inc. | ADRO |
-$19.4 M -$82.4 M (FY19) with -$5 M discontinued progam loss |
-$0.24 | $213.6 M | 2021 | |
| Alnylam Pharmaceuticals | ALNY |
-$221.2 M -$886.1 M, FY19 |
-$1.98 -$6.50, FY19 |
$1.55 B |
Not (N/N) needed |
|
| Applied Genetic Technologies | AGTC |
-$10.5 M (Q4 June) -$1.89 M (FY19) |
-$0.58 -$0.11 (FY19) |
$82 M Raise $32.5 (2/6/2020) |
2022 | |
| Athersys, Inc. | ATHX |
-$9.9 M -$44.6 M (FY19) |
-$0.06 -$0.29 |
$44.6 M | Q3/2021 | |
| Adverum Biotechnologies, Inc. | ADVM |
-$18.9 M -$64.4 M (FY19) |
-$0.29 -$1.01 |
$166 M | 2022 | |
| AxoGen, Inc. | AXGN |
-$7 M -$29 .1 M |
-$0.18 -$0.74 |
$102.5 M | N/N | |
| Bellicum Pharmaceuticals | BLCM |
-$29 M -$112.5 M (FY19) |
-$5.82 -$24.01 |
$93.8 M | Q2/2021 | |
| BioLife Solutions, Inc. | BLFS |
+$481 K or +$0.02 +$11.1 M (FY19) or +$0.42 |
$6.448 M | N/N | ||
| Biostage, Inc. | BSTG |
-$1.6 M -$8.3 M (FY19) |
-$0.21 -$1.21 |
$900 K (with-$679 K in accts. payable and liabilities) |
early Q2/2020 | |
| bluebird bio | BLUE |
-$323.3 M -$789.6 M (FY19) |
-$3.55 | $124 B | 2022 | |
| Brainstorm Cell Therapeutics | BCLI |
No Q4 -$23.2 M, FY19 |
No Q4 -$1.06, FY19 |
$600 K | 2020 | |
| Caladrius Biosciences. | CLBS |
-$5 M -$19.4 M (FY19) |
-$0.47 -$1.88 (FY19) |
$25.16 M | Q2/2021 | |
| Cellectis SA | CLLS |
-$37 M -$102 m (FY19) |
-$0.88 -$2.41 (FY19) |
$364 M | 2022 | |
| CRISPR Therapeutics | CRSP |
+$30.5 M or +$0.51 per share +$6.9 M or +$1.17 per share (FY19) |
|
$943.8 M | 2023 | |
| Editas Medicine | EDIT |
-437.8 M -$133.7 M |
-$0.74 -$2.68 |
+$457.1 M | 2022 | |
| Fate Therapeutics | FATE |
-$28.3 M -$98.14 M (FY19)
|
-$0.37 -$1.44 (FY19) |
+$260.9 M | 2021 | |
| Global Blood Therapeutics | GBT |
-499.5 M (Q4) -$266.76 M (FY19)
|
-$1.73 (Q4) -$4.71 (FY19) |
$695 M $150 M loan (Pharmakon Advisors) |
2022 | |
| Homology Medicine | FIXX |
-$24.2 M $103.9 M (FY19) |
-$0.55 -$2.47 |
$262.4 M | Q4/2021 | |
| Intellia Therapeutics | NTLA |
-$28.3 M -$683.5 M (FY18) |
-$0.51 -$2.11 (FY19) |
$284.5 M ATM usuage of $124.9 M |
2021 | |
| Precigen (fomerly Intrexon (XON) | XON |
-$169.2 M (FY19) -$322.3 M from discontinued operations +$70.4 M non-cash charges |
-$1.09 (FY19) -$2.09 |
+$75.1 M | 2020 | |
| Ionis Pharmaceuticals | IONS |
+$204 M or +$1.31 per share $303 M or $2.12 per share (FY19) |
$2.5 B | N/N | ||
| Mesoblast Limited | MESO |
-$24.58 M(Q4) -$30.06 M (FY 6 mo)
|
-$4.60(Q4) -$5.82 |
$81.3 M Acess to $62.5 Mfrom existing financial faclities |
2021 | |
| MiMedx Group, Inc | MDXG | Restating | ||||
| Pluristem Therapeutics, Inc. | PSTI | -$6.37 M | -$0.40 |
$17.5 M ($4 M raise 1/2020) |
2021 | |
| ReNeuron Group PLC | RENE.L | looking | ||||
| Regenxbio | RGNX |
-$26.5 M (q4) -$94.7M (FY19) |
-$0.72 -$2.58 |
$400 M | 2022 | |
| Sage Therapeutics | SAGE |
-$168.7 M (Q4) -$680.2 M (FY19) |
-$3.25 -$13.38 |
$1 B | N/N | |
| Sangamo Biosciences, Inc. | SGMO |
+$4.6 M or $0.04 per share (Q4) -$95.2 M or -$0.85 per share (FY19) |
$3.85 M | 2023 | ||
| Solid Biosciences | SLDB |
-$31.9 M -$117.2 M (FY19) |
No Q4 # -$2.91 |
$83.5 M | 2021 | |
| Stemline Therapeutics, Inc. | STML |
-$17.7 M -$76.79 M (FY19) |
-$0.38 -$1.83 |
$164.4 | Q2/2021 | |
| Ultragenyx | RARE |
-$93.8 M -$402.7 M (FY19) |
-$1.62 -$7.12 |
$760.4 M | 2022 | |
| uniQure N.V. | QURE |
-$124.2 M (FY19) |
-$3.11 FY19 |
$377.8 M | 2022 | |
| Verastem, Inc. | VSTM |
-$38.8 M -$126 M |
-$0.51 -$1.69 |
$113 M add $92 M (pp on 3/3/2020) |
Q4/2021 | |
| Vericel Corporation | VCEL | +$9.5 M or +$0.20 per share |
-$9.7 M (FY19) |
-$0.22 (FY19) |
$79 M | 2022 |
| Voyager Therapeutics | VYGR |
-$12.6 M -$43.6 M (FY19) |
-$0.34 -$1.21 (FY19) |
$281.5 M | mid-2022 |
